People · Operator
Named in public records as an officer, director or promoter · active 2013–2024 · Biotechnology, Other Health Care, Manufacturing, Other Technology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vaxxinity, Inc. | — | Biotechnology | Growth/Late | $1.4B | $927.3M | 2021 |
| Paradromics, Inc. | — | Other Health Care | Series C | $96.9M | $569.6M | 2023 |
| Halo Industries, Inc. | — | Manufacturing | Series C | $46.0M | $321.3M | 2024 |
| C19 Corp. | — | Biotechnology | Series B | $32.9M | $684.4M | 2020 |
| Tachyus Corp | — | Other Technology | Series A | $31.4M | $124.8M | 2013 |
| Nelumbo Inc. | — | Other | Series A | $15.9M | $211.9M | 2019 |
| polySpectra, Inc. | — | Other Technology | Series A | $8.4M | $19.7M | 2019 |
| Space Apprentices Enterprise Inc. | — | Other | Series A | $8.1M | $121.9M | 2018 |
| Unlimited Tomorrow, Inc. | — | Other Technology | Series A | $6.7M | $21.2M | 2019 |
Dakin Sloss at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Dakin Sloss on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| PETER DIAMANDIS | 2 | 10 |
| Brandon Simmons | 2 | 5 |
| Zia Huque | 2 | 3 |
| Louis Reese | 2 | 2 |
| Mei Mei Hu | 2 | 2 |
| Allen Morgan | 1 | 19 |
| Jonathan Cohen | 1 | 5 |
| Elizabeth Stein | 1 | 4 |
| Amy Kruse | 1 | 4 |
| Scott Nolan | 1 | 4 |
| Jeremy Arendt | 1 | 4 |
| Thomas Krummel | 1 | 3 |
| Adam Kablanian | 1 | 3 |
| Ron Kelly | 1 | 3 |
| LAURA SMOLIAR | 1 | 2 |
| Rakesh Jain | 1 | 2 |
| James Burrows | 1 | 2 |
| Helmy Eltoukhy | 1 | 2 |
| Keisuke Ide | 1 | 2 |
| Lev Khasis | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.